

## COMPANY OVERVIEW

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.



### MISSION

Developing innovative therapies against cancer



### VISION

Eliminate Cancer. Improve Life.

- Led by broad, proprietary technology platforms for the discovery and development of allogeneic (off-the-shelf) and autologous (personalized) chimeric antigen receptor T cell (CAR T) therapies
  - Leader in Natural Killer Group 2D (NKG2D) receptor CAR T cell therapy landscape
- NKG2D receptor-based CAR T candidates target eight different stress ligands expressed on the surface of both hematological malignancies and solid tumor cells
- Advancing the field of allogeneic CAR T development by exploring two proprietary, non-gene edited technologies — T cell receptor Inhibitory Molecule (TIM) and short hairpin RNA (shRNA)
  - Builds upon Company's All-in-One Vector approach
- Robust intellectual property position related to allogeneic and NKG2D CAR T therapies
- Supported by in-house GMP grade cell therapy manufacturing facility

## COMPANY FAST FACTS



### Headquarters:

Mont-Saint-Guibert, Belgium



### Total Employees:

~100

## FINANCIAL OVERVIEW



### NASDAQ/EURONEXT:

CYAD

### Market Cap:

~69,77M

### Cash Balance:

€12.2 million (\$14.3 million)

(all figures reported as of March 31, 2021)

## MANAGEMENT TEAM

### Filippo Petti

Chief Executive Officer &  
Chief Financial Officer

### Philippe Dechamps

Chief Legal Officer

### David Gilham, Ph.D.

Chief Scientific Officer

### CHARLES MORRIS, M.D.

Chief Medical Officer

### Frédéric Lehmann, M.D.

VP Clinical Development & Medical  
Affairs

### Philippe Nobels

VP Human Resources

### Stephen Rubino, Ph.D.

Chief Business Officer



## Allogeneic

	TARGET	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
⊕ <b>CYAD-101</b>	NKG2DL	mCRC	██████████	██████████		
⊕ <b>CYAD-103</b>	NKG2DL	Solid Tumors	██████████			
⊕ <b>CYAD-211</b>	BCMA	r/r MM	██████████	██████████		
⊕ <b>CYAD-221</b>	CD19	B-cell malignancies	██████████			
⊕ <b>CYAD-231</b>	NKG2DL x Undisclosed	Solid Tumors	██████████			

## Autologous

	TARGET	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
⊕ <b>CYAD-02</b>	NKG2DL	r/r AML/MDS	██████████	██████████		

## PARTNERSHIPS

Since its incorporation, Celyad Oncology has built strong partnerships with key international academic institutions and strategic organizations in order to maximize the therapeutic potential of its product candidates and intellectual property.



## UPCOMING ANTICIPATED MILESTONES

- CYAD-101 in mCRC**  
Report preliminary data from expansion cohort of alloSHRINK trial - Expected 1H 2021
- CYAD-101 in mCRC**  
Initiate Phase 1b KEYNOTE-B79 trial with KEYTRUDA® in patients with MSS / pMMR disease - Expected 1H 2021
- CYAD-211 in r/r MM**  
Report proof-of-concept data on shRNA technology as allogeneic platform from initial dose cohorts of Phase 1 IMMUNICY-1 trial - announced for Poster presentation at EHA 2021
- CYAD-02 in r/r AML and MDS**  
Additional data from CYAD-02 Phase 1 CYCLE-1 trial - Expected 1H 2021

## CONTACT

Axis Business Park

Rue Edouard Belin 2  
1435 Mont-Saint-Guibert

+32(0) 10 39 41 00  
+32(0) 10 39 41 41 (Fax)

info@celyad.com